Mitchell Finer, Ph.D.

Mitchell (Mitch) H. Finer Ph.D. has served as a member of Adverum’s board of directors since the completion of the merger of Avalanche Biotechnologies, a company he co-founded, and Annapurna Therapeutics in 2016. He is a managing director at MPM Capital and is a member of the board of directors of portfolio companies Semma Therapeutics and TCR2 Therapeutics. Since joining MPM in 2015, he founded Oncorus, Inc., where he serves as chief executive officer and chief scientific officer. For three decades, Dr. Finer has focused on drug development utilizing the novel platforms of cell and gene therapy, cancer immunotherapy, and regenerative medicine, working to develop products from conception through Phase 3 clinical programs in the United States and Europe. Prior to MPM, Mitch served as the chief scientific officer of bluebird bio. Previously, Dr. Finer served as chief executive officer of Intracel Holdings Corporation and Genteric, Inc., vice president of research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi), and senior vice president of development at Novocell, Inc. (now ViaCyte, Inc.). Dr. Finer received a Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in Biochemistry and Microbiology from the University of California at Berkeley. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at MIT.